Description
The drug resistant cell line K562 AZQ has been developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone). The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
Adherent Suspension
Suspension
Suggested Medium
RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
Quality Control
K562 AZQR Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Morphology
Lymphoblastoid
Shippment
K562 AZQR Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
K562 AZQR Cell Line is for research use only